Eskelin S, Kivelä T
Department of Ophthalmology, Helsinki University Central Hospital, Helsinki, Finland.
Br J Ophthalmol. 2002 Mar;86(3):333-8. doi: 10.1136/bjo.86.3.333.
To investigate the current referral pattern and delays in treatment of patients with primary uveal melanoma.
184 consecutive Finnish patients with uveal melanoma diagnosed between July 1994 and June 1999 were eligible, and 159 were enrolled (inclusion rate, 86%). Their mean age was 60 years (range 14-87). The dates of visits to dispensing optician, physician, ophthalmologist and ocular oncologist, the presence of symptoms, and reason for consultation were determined by structured telephone interview. Time intervals to treatment planning and treatment were calculated.
139 patients (87%) had symptoms at presentation and 44 patients (28%) had been seen by an ophthalmologist less than 2 years previously. The median height of the tumour was 6 mm (range, 1.0-17.0) and its largest basal diameter 11 mm (range 2.5-22.0) at diagnosis. Melanoma developed from a previously detected presumed naevus in 13 patients (8%). When the first contact was a dispensing optician (15%) the median time to treatment planning was 22 days (range 1-1156). When a physician other than an ophthalmologist (19%) was contacted the delay was 68 days (range 0-1283) and when an ophthalmologist (65%) was seen it was 34 days (range 1-1426). These differences were not significant (p=0.32). The chance of being referred at first visit was 89%. Median time to treatment was not associated with symptoms (p=0.16) and tumour volume (p=0.29), but it was significantly different between patients who were and were not referred at first visit (140 days v 34 days; p<0.001) and between those treated by ruthenium and iodine brachytherapy (59 days v 33 days; p=0.009).
Analysis of delays in management indicates that earlier treatment could be achieved if dilated fundus examinations were performed without exceptions, all suspicious naevi were referred for a second opinion, and if the patients with melanoma were referred to the ocular oncology service concurrently with staging examinations done at the regional hospital.
研究原发性葡萄膜黑色素瘤患者当前的转诊模式及治疗延迟情况。
1994年7月至1999年6月间连续诊断的184例芬兰葡萄膜黑色素瘤患者符合条件,159例被纳入研究(纳入率86%)。他们的平均年龄为60岁(范围14 - 87岁)。通过结构化电话访谈确定患者拜访配镜师、内科医生、眼科医生和眼科肿瘤学家的日期、症状的存在情况以及咨询原因。计算至治疗计划制定和治疗的时间间隔。
139例患者(87%)就诊时存在症状,44例患者(28%)在不到2年前看过眼科医生。诊断时肿瘤的中位数高度为6毫米(范围1.0 - 17.0),最大基底直径为11毫米(范围2.5 - 22.0)。13例患者(8%)的黑色素瘤由先前检测到的疑似痣发展而来。当首次接触是配镜师时(15%),至治疗计划制定的中位数时间为22天(范围1 - 1156天)。当接触的是眼科医生以外的内科医生时(19%),延迟时间为68天(范围0 - 1283天),而看眼科医生时(65%)为34天(范围1 - 1426天)。这些差异无统计学意义(p = 0.32)。首次就诊时被转诊的几率为89%。至治疗的中位数时间与症状(p = 0.16)和肿瘤体积(p = 0.29)无关,但在首次就诊时被转诊和未被转诊的患者之间(140天对34天;p < 0.001)以及接受钌和碘近距离治疗的患者之间(59天对33天;p = 0.009)有显著差异。
对管理延迟情况的分析表明,如果无一例外进行散瞳眼底检查,所有可疑痣均转诊以获取第二种意见,并且葡萄膜黑色素瘤患者在区域医院进行分期检查的同时转诊至眼科肿瘤服务部门,则可以实现更早的治疗。